Immunomedics Receives FDA Breakthrough Therapy Designation For Breast Cancer Drug
February 07, 2016 at 11:24 AM EST
Breakthrough Therapy Designation gives priority review to the drug in question. That means instead waiting 10 to 12 months for a drug review they only need wait 3 to 4 months after NDA submission.
